Low Cost Biosensor to Be Based on Printing Technologies
|
By LabMedica International staff writers Posted on 14 Sep 2011 |
Scientists intend to use the latest printing technologies to develop a low cost biosensor capable of diagnosing a range of health conditions.
Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.
Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.
The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.
“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.
“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”
In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.
The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.
The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.
Related Links:
Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business
Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.
Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.
The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.
“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.
“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”
In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.
The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.
The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.
Related Links:
Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








